Can an ¹⁸F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma?

This study examined the value of a novel 1-step labeled integrin α(v)β3-targeting (18)F-AlF-NOTA-PRGD2 (denoted as (18)F-RGD) scan in assessing sensitivity to concurrent chemoradiotherapy (CCRT) in patients with newly diagnosed glioblastoma multiforme (GBM). Twenty-five patients with newly diagnosed...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of nuclear medicine (1978) 2016-04, Vol.57 (4), p.524-529
Hauptverfasser:	Zhang, Hui, Liu, Ning, Gao, Song, Hu, Xudong, Zhao, Wei, Tao, Rongjie, Chen, Zhaoqiu, Zheng, Jinsong, Sun, Xiaorong, Xu, Liang, Li, Wanhu, Yu, Jinming, Yuan, Shuanghu
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Brain Neoplasms - therapy Chemoradiotherapy - methods Coordination Complexes - pharmacokinetics Coordination Complexes - therapeutic use Disease Progression Female Glioblastoma - therapy Humans Magnetic Resonance Imaging Male Middle Aged Neoplasm, Residual - therapy Peptides, Cyclic - pharmacokinetics Peptides, Cyclic - therapeutic use Positron-Emission Tomography Predictive Value of Tests Radiopharmaceuticals - pharmacokinetics Radiopharmaceuticals - therapeutic use Reproducibility of Results Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!